Year-Long Exercise Program Cuts Atrial Fibrillation Burden by 45 Percent in Clinical Trial
The NEXAF trial, presented at the European Society of Cardiology Congress 2026, found that a one-year tailored exercise program reduced atrial fibrillation burden by 45 percent in patients with symptomatic AFib. Participants in the exercise group also had 37 percent fewer total hospitalizations.
A one-year tailored exercise program cut atrial fibrillation burden by 45 percent in patients with symptomatic AFib, according to the NEXAF trial presented at the European Society of Cardiology Congress 2026.
The trial enrolled 295 patients with symptomatic, non-permanent atrial fibrillation. Participants in the exercise group started with supervised, high-intensity sessions over the first four to six weeks, then transitioned to home-based exercise supported by remote monitoring and wearable technology.
After one year, patients in the exercise group spent 3.9 percent of their time in AFib, compared to 7.1 percent in the usual-care group. That represents a 45 percent relative reduction in arrhythmia burden.
The exercise group also had 37 percent fewer total hospitalizations and 46 percent fewer AFib-related hospitalizations. Participants showed improvements in resting heart rate and cardiorespiratory fitness.
Separate research published earlier in 2026 in the Journal of Interventional Cardiac Electrophysiology found that patients who had undergone catheter ablation and engaged in at least 90 minutes of moderate physical activity per week had a nearly 50 percent lower risk of AFib recurrence. Even 15 minutes of activity on most days was linked to better outcomes.
Medical experts say the findings support treating exercise as a primary medical intervention for AFib, not just a lifestyle suggestion. They recommend that patients begin with a medical evaluation and supervised sessions to develop a safe, individualized plan.
Atrial fibrillation affects more than 6 million Americans and is the most common serious heart rhythm disorder. It increases the risk of stroke, heart failure, and other cardiovascular complications. Current treatments include medications, cardioversion, and catheter ablation, but recurrence rates remain high.
